Kenneth J. Mandell

Dr. Mandell is a Harvard-trained ophthalmologist who founded LayerBio with the aim of developing a drug-eluting intraocular lens (IOL) for cataract surgery. He has more than 10 granted U.S. patents and is co-inventor of Oyster Point Pharma’s OC-01 treatment for dry eye disease and Aldeyra’s reproxalap eye drop for ocular inflammation. Dr. Mandell has personally contributed to more than a dozen Investigational New Drug (IND) applications and overseen the conduct of numerous Phase 1-3 clinical trials in the field of ophthalmology. He currently serves as a strategic advisor to Aramis Biosciences, a Harvard spin-off developing novel therapies for eye disease, and as Medical Monitor for clinical trials at the National Eye Institute at the National Institutes of Health.